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Abstract. 
 
Caspase-11, a member of the murine caspase 
family, has been shown to be an upstream activator of 
caspase-1 in regulating cytokine maturation. We dem-
onstrate here that in addition to its defect in cytokine 
maturation, caspase-11–deﬁcient mice have a reduced 
number of apoptotic cells and a defect in caspase-3 acti-
vation after middle cerebral artery occlusion (MCAO), 
a mouse model of stroke. Recombinant procaspase-11 
can autoprocess itself in vitro. Puriﬁed active recombi-
nant caspase-11 cleaves and activates procaspase-3 very 
efﬁciently. Using a positional scanning combinatorial li-
brary method, we found that the optimal cleavage site 
of caspase-11 was (I/L/V/P)EHD, similar to that of up-
stream caspases such as caspase-8 and -9. Our results 
suggest that caspase-11 is a critical initiator caspase re-
sponsible for the activation of caspase-3, as well as 
caspase-1 under certain pathological conditions.
Key words: caspase-11 • initiator caspase • stroke • 
middle cerebral artery occlusion • apoptosis
 
Introduction
 
Mammalian caspases are a family of cysteine proteases in-
volved in regulating cytokine maturation and apoptosis
(Cryns and Yuan, 1998). Caspases can be classified ac-
cording to their amino acid sequence homology into
caspase-1, -3, and -9 subfamilies. The caspase-1 subfamily
includes caspase-1, -4, -5, and -11. Since the predominant
defect of caspase-1 knockout mice is the inability to pro-
cess prointerleukin-1
 
b
 
 (pro–IL-1
 
b
 
)
 
1
 
, the major function of
caspase-1 is believed to be regulating cytokine maturation
(Kuida et al., 1995; Li et al., 1995). Caspase-11 is a murine
caspase that shares the highest homology with human
caspase-4 (60% identity). The expression of caspase-11 is
undetectable in healthy mice and highly inducible upon in-
jection of lipopolysaccharide (LPS; Wang et al., 1996).
Caspase-11 does not process pro–IL-1
 
b
 
 directly. Never-
theless, caspase-11 mutant mice are deficient in the pro-
cessing and secretion of IL-1
 
b
 
 (Wang et al., 1998). We
showed that caspase-11 can physically interact with cas-
pase-1 to promote its activation. Based upon these data,
we proposed that elevated expression of caspase-11 under
pathological condition is directly responsible for activation
of caspase-1, and thus, caspase-11 is an upstream regulator
of caspase-1 (Wang et al., 1998).
The caspase-3 subfamily includes caspase-3, -6, -7, -8,
and -10 (Cryns and Yuan, 1998). Among this family,
caspase-3 shares highest homology with caspase-7 and
both have short prodomains; whereas caspase-6, -8, and
-10 have long prodomains. Caspase-3 has been shown to
be a major execution caspase that acts downstream in the
apoptosis pathway and is involved in cleaving important
substrates such as ICAD (inhibitor of caspase activated
DNase), which activates the apoptotic DNA ladder-form-
ing activity of CAD (caspase activated DNase; Enari et al.,
1998; Sakahira et al., 1998). The major route of activating
short prodomain caspases is through direct proteolytic
processing. Two known pathways that can activate pro-
caspase-3 are through proteolytic cleavage by caspase-8
and -9. In the Fas apoptosis pathway, the activation of Fas
receptor induces the formation of death inducing signaling
complex (DISC) which recruits and activates caspase-8
(Kischkel et al., 1995; Muzio et al., 1996). In Fas type I
cells, activated caspase-8 directly activates procaspase-3 by
cleavage (Scaffidi et al., 1998). In apoptosis, where mito-
chondria play a critical role, the release of cytochrome c
from damaged mitochondria induces the formation of cy-
tochrome c/Apaf-1/caspase-9 complex (Li et al., 1997).
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Apaf-1 is a mammalian homologue of 
 
Caenorhabditis ele-
gans
 
 cell death gene product Ced-4 (Zou et al., 1997). The
interaction of cytochrome c, Apaf-1, and caspase-9 trig-
gers the activation of caspase-9 that in turn activates pro-
caspase-3 through direct proteolytic processing (Li et al.,
1997). Thus, caspase-8 and -9 have been known as the two
major upstream activators of caspase-3. Caspase-8 and -9
mutant mice exhibit severe defects in developmental apop-
tosis, suggesting that they are critical for activation of apop-
tosis and caspase-3 during development (Kuida et al.,
1998; Varfolomeev et al., 1998).
Caspases may be involved in both acute and chronic
neurodegenerative diseases (Friedlander and Yuan, 1998).
Irreversible caspase inhibitors, zVAD.fmk and zDEVD.
fmk, protected brains from ischemic injury and improved
neurological deficits in both mouse and rat (Hara et al.,
1997b). Caspase-3–like enzyme activity and the activated
caspase-3 subunit are detected in ischemic brain sam-
ples (Namura et al., 1998). Intraventricular injection of
DEVD.fmk significantly reduced middle cerebral artery
occlusion (MCAO)-induced apoptosis, suggesting that
caspase-3 may play a critical role in ischemic brain injury
(Hara et al., 1997b). As caspase-3 is a short-prodomain
caspase, it is usually activated by an upstream caspase
through direct proteolytic cleavage. Although caspase-3
has been implicated in a number of pathological condi-
tions, including brain ischemia, the identity of the up-
stream caspase(s) is not known. We show here that
caspase-11 fits all the criteria to be this upstream caspase
in activation of caspase-3 under pathological conditions.
Caspase-11 mutant mice are defective in apoptosis and
caspase-3 activation induced by brain ischemic injury. Ac-
tivated caspase-11 is an efficient activator of caspase-3 in
vitro. Combinatorial library analysis showed that the pre-
ferred cleavage sequence of caspase-11 is (I/L/V/P)EHD,
similar to that of caspase-8 and -9 (Thornberry et al.,
1997). In addition, procaspase-11 can process itself in
vitro. We propose that caspase-11 is an upstream caspase
responsible for the activation of caspase-3, as well as
caspase-1, under pathological conditions.
 
Materials and Methods
 
Animals
 
Caspase-11 knockout mice have been described previously (Wang et al.,
1998). In brief, mutant ES cell clones carrying a null mutant caspase-11 al-
lele were injected into C57BL/6J blastocysts. The resulting chimeric males
were then mated with C57BL/6J 
 
3
 
 DBA2 F1 females to obtain germline
transmission of the mutant allele. Chimera of clone 444 produced germ-
line transmitted mutant mice. The offsprings from clone 444 were back-
crossed to C57BL/6J four times. Heterozygous littermates of this F4 were
mated and the resulting offspring were used in this study. To ensure ge-
netic background homogeneity, littermates of wild-type and caspase-11
 
2
 
/
 
2
 
mice were used in each group. The genotype was determined by Southern
blot analysis as described previously (Wang et al., 1998).
To induce ischemia brain injury, 6–8-wk-old male mice were anesthe-
tized with 1.5% halothane and maintained in 1% halothane in 70% N
 
2
 
O
and 30% O
 
2
 
 using a Fluotec 3 vaporizer (Colonial Medical). Permanent
ischemia was induced with an 8.0 nylon monofilament coated with a sili-
cone resin-hardener mixture (Xantopren and Elastomer Activator;
Bayer Dental) as described previously (Hara et al., 1997b). The filament
was introduced into the left common carotid artery, advanced into the an-
terior cerebral artery, and left there until the animal was killed for immu-
nohistochemistry and TUNEL assay.
 
Construction of Plasmid
 
The construction of expression plasmid of caspase-11 was made by PCR
amplification using pJ667 as a template (Wang et al., 1998). The prim-
ers used are: SY6, GAGGATCCCATGGCTGAAAACAAACACCCT;
and mNO/BH2, TTGGATCCGTCAGTTGCCAGGAAAGAGGT. The
PCR fragment was cloned into the BamH1 site of pET-15b and named
pS15.
The cleavage site mutation of caspase-3, D175A, was created by PCR
using human caspase-3 as a template. The primers used for amplifying the
5
 
9
 
 half of caspase-3 cDNA were: SJ1, ATGGAGAAGACTGAAAACT-
CAG; and SJ2, CAACACCAGTGGCTGTCTCAA. The primers for am-
plifying the 3
 
9
 
 half of caspase-3 cDNA were: SJ3, TTGAGACAGC-
CAGTGGTGTTG; and SJ4, CTTTAGTGATAAAAATAGAGTTC.
The 5
 
9
 
 and 3
 
9
 
 half of caspase-3 cDNA fragments were used as templates
for the third PCR with SJ1 and SJ4 as primers. The resulting 850-bp frag-
ment was cloned into pCDNA3 at EcoRV site. The D175A mutation was
verified by sequencing and used for in vitro translation.
 
Preparation of Purified Recombinant
Caspase-11 Protease
 
The expression constructs were transformed into 
 
Escherichia coli 
 
strain
BL21 (DE3).
To make bacterial lysates, 10 ml of overnight culture from a single col-
ony was diluted 1:100 and grown for 2.5 h until OD
 
600
 
 reaches 0.5–1.0.
Then, caspase-11 was induced by adding 0.3 mM of isopropyl-1-thio-
 
b
 
-
 
D
 
-galactopyranoside (IPTG) and grown for another 2.5 h in a 37
 
8
 
C
shaker. The bacteria were harvested and sonicated in 1 ml lysis buffer con-
taining 50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 0.5 mM sucrose, and 5%
glycerol. Protease inhibitors (1 mM PMSF, 5 
 
m
 
g/ml pepstatin, and 10 
 
m
 
g/
ml leupeptin) were also added. After centrifugation at 10,000 
 
g
 
 the super-
natant was mixed with 2 ml of nickel-charged resin (Qiagen) and then in-
cubated for 2 h at 4
 
8
 
C with rotation. The beads were then washed serially
with 20 ml of lysis buffer plus 1 M NaCl and lysis buffer alone. The bound
caspase-11 was eluted with 5 ml lysis buffer containing 125 mM imidazole
and verified by SDS-PAGE and Coomassie blue staining.
 
In Vitro Cleavage Assay
 
In vitro translation of 
 
35
 
S-labeled proteins was made by using TNT-cou-
pled transcription/translation kit (Promega) in the presence of [
 
35
 
S]me-
thionine. 
 
35
 
S-labeled proteins were incubated with 0.5 
 
m
 
g of purified
caspase-11 in the presence of 50 
 
m
 
M Tris-HCl, pH 8.0, 0.5 mM EDTA, 0.5
mM sucrose, and 10 mM DTT together with protease inhibitors in a total
volume of 10 
 
m
 
l. The mixture was incubated at 30
 
8
 
C for 2 h. The reaction
was terminated by addition of equal volume of 2
 
3
 
 SDS protein sample
buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 5% 
 
b
 
-mercaptoethanol, and
0.01% bromophenol blue) and then analyzed by SDS-PAGE and autora-
diography.
 
Cell Culture
 
L929 (mouse fibrosarcoma cell line) cells were maintained in DME sup-
plemented with 10% FCS.
 
Immunoblot and Immunoprecipitation Assay
 
Generation of mAb against caspase-11 (17D9, hybridoma culture super-
natant) was described previously (Wang et al., 1996). For immunoblotting,
tissue samples were ground in liquid N
 
2
 
 and the resulting tissue powder
was solubilized in 0.7 ml of IP lysis buffer (50 mM Hepes, pH 7.5, 150 mM
NaCl, 1 mM EDTA, and 1% NP-40) with protease inhibitors (1 mM
PMSF, 10 
 
m
 
g/ml leupeptin, and 5 
 
m
 
g/ml pepstatin). After incubating on ice
for 10 min, samples were centrifuged at 13,000 rpm in a microfuge at 4
 
8
 
C
for 20 min. Protein concentration was measured using BioRad protein as-
say reagent. 60 
 
m
 
g of protein was subjected to SDS-PAGE on a 15% gel.
Proteins were then transferred onto immobilon-P membrane (Millipore)
and incubated with blocking solution containing 5% skim milk in TBST
(50 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween 20) for 1 h at room
temperature. The membrane was then incubated with primary antibody in
blocking solution at 4
 
8
 
C overnight. After washing three times with TBST
for 10 min each, the membrane was incubated with HRP-conjugated anti-
rat or anti–rabbit IgG (Jackson ImmunoResearch) for 40 min at room
temperature. After washing three times, the bound antibody was revealed
using the ECL Western blotting reagent (Amersham Pharmacia Biotech). 
Kang et al. 
 
Caspase-11 Activates Caspase-3 under Pathological Conditions
 
615
 
For immunoprecipitation, half of the mouse brain was ground in liquid
N
 
2
 
 and solubilized in 700 
 
m
 
l of lysis buffer. The resulting lysate superna-
tant (total 1 mg of protein) was incubated with 50 
 
m
 
l 17D9 overnight at
4
 
8
 
C with rotation, followed by incubation with protein G-coupled agarose
beads for 40 min. The immune complexes were resolved by SDS-PAGE
and analyzed by immunoblotting using 17D9.
 
Immunohistochemistry
 
After MCAO or LPS challenge, mice were anesthetized and transcar-
dially perfused with cold PBS and then with 4% paraformaldehyde in
PBS. Brains were dissected, embedded in OCT medium, and were then
frozen on top of dry ice. The frozen blocks were kept in 
 
2
 
80
 
8
 
C until use.
5-
 
m
 
m sections were made in a Leica CM3000 cryostat. Sections were then
postfixed in ice cold ethanol/acetic acid (2:1) solution for 5 min. After
brief washing with PBS, endogenous peroxidase activity was quenched by
incubating sections with 0.3% hydrogen peroxide in PBS for 30 min when
TSA signal amplification kit (NEN Life Science Products) was used for vi-
sualization. Sections were then incubated with 10% normal goat serum in
PBS containing 0.1% Triton X-100 for 1 h at room temperature. When
secondary antibody is biotin/avidin system, samples were first blocked
with Vector Laboratories’ Biotin/Avidin blocking kit before incubating
with normal goat serum. After blocking, sections were incubated with
drops of anticaspase-11 monoclonal (undiluted 17D9), anticaspase3p20
(CM1) rabbit polyclonal (1:2,000), anti-NeuN mouse monoclonal (1:1,000;
Chemicon International), or anti-GFAP (glial fibrillary acidic protein)
rabbit polyclonal (1:500; DACO) antibody in PBS containing 1% normal
goat serum and 0.1% Triton X-100 at 4
 
8
 
C overnight in a humid chamber.
For detection of microglial cells, biotin-conjugated B
 
4
 
 isolectin (5 
 
m
 
g/ml)
was used. Samples were then washed four times with PBS containing 0.1%
Triton X-100 for 5 min each, followed by incubation with secondary anti-
bodies in PBS containing 1% normal goat serum and 0.1% Triton X-100
for 30 min at room temperature. For the detection of caspase-11, HRP-
conjugated anti-rat goat IgG (Jackson ImmunoResearch) and TSA signal
amplification kit were used following manufacturer’s protocol. For the de-
tection of caspase-3, NeuN, and GFAP, matching secondary antibodies
conjugated with biotin were used. After washing, biotin-decorated sam-
ples were incubated with Texas red- or FITC-conjugated streptavidin
(Jackson ImmunoResearch) for 30 min at room temperature. Tissue sec-
tions were then counterstained with Hoechst 33258 dye (1 
 
m
 
g/ml in PBS;
Sigma Chemical Co.) for 10 min at room temperature. After washing,
slide glass samples were mounted with mounting medium (1 mg/ml 
 
p
 
-phe-
nylendiamine in PBS containing 90% glycerol). Samples were examined
using an Axiovert 135 microscope (Carl Zeiss, Inc.) and images were re-
corded using Northern Exposure software.
For TUNEL assay, ethanol/acetic acid postfixed samples were briefly
washed and then treated with proteinase K (20 
 
m
 
g/ml in PBS) for 15 min
at room temperature. After washing with PBS, samples were processed
using Apoptag kit (Intergen) according to the manufacturer’s manual.
Samples were also counterstained with Hoechst 33258.
 
Enzyme Activity Assay
 
To see if caspase-11 can activate procaspase-3 or -1, 15 
 
m
 
g of purified re-
combinant caspase-11 (pS15) and/or 10 
 
m
 
g of recombinant procaspases
were added into Hepes buffer (50 mM, pH 7.4) containing 2 mM DTT and
12 
 
mM
 
 fluorogenic peptide substrates (acDEVD.amc or acYVAD.amc) in
a total volume of 300 
 
m
 
l. Fluorescence as a result of caspase activation was
measured at 10-s intervals using Aminco Bowman Series 2 Luminescence
spectrometer (excitation wavelength 
 
5 
 
380 nm, emission wavelength 
 
5
 
460 nm).
 
Substrate Specificity Screening
 
The design, synthesis, and validation of the PS-SCL have been described
elsewhere (Rano et al., 1997). Each of the 60 samples (20 amino acids 
 
3
 
 3
sublibraries) of the PS-SCL was prepared as a stock of 
 
z
 
10 mM in
DMSO. To determine protease specificity, 2.3 nM caspase-11 was added
to reaction mixtures containing 100 
 
m
 
M substrate mix, 100 mM Hepes,
10% sucrose, 0.1% CHAPS, 10 mM DTT, pH 7.5, in a total volume of 100
 
m
 
l. Under these conditions, the final concentration of each individual
compound is 
 
z
 
0.25 
 
m
 
M. Production of AMC was monitored continuously
at room temperature in a Tecan Fluostar 96-well plate reader using an ex-
citation wavelength of 380 nm and an emission wavelength of 460 nm.
 
Results
 
Protection of Apoptotic Cell Death in
Caspase-11–deficient Mice
 
Previous studies suggesting a role of caspase-11 as an es-
sential activator of caspase-1 (Wang et al., 1996, 1998) and
a potential role of caspase-1 in ischemic brain injury
(Friedlander et al., 1997; Hara et al., 1997a,b; Schielke et
al., 1998) led us to investigate the involvement of caspase-
11 in apoptosis induced by MCAO, a mouse model of
stroke. Caspase-1 knockout mice showed resistance to isch-
emic brain injury (Schielke et al., 1998). However, since
we failed to detect the LPS stimulated caspase-11 induc-
tion in caspase-1 knockout mice generated both by Kuida
et al. (1995) and Li et al. (1995; Fig. 1 A), we cannot distin-
guish whether loss of caspase-1 or caspase-11 expression is
directly responsible for the protection against ischemia-
induced apoptosis. The expression of caspase-1 in caspase-
11 mutant mice, on the other hand, is completely normal
(Wang et al., 1998). To determine whether caspase-11 is
critical for ischemic brain injury, we subjected caspase-11
mutant mice and their littermate wild-type controls to
MCAO. Blood flow was blocked in the territory of the
middle cerebral artery of the left hemisphere by inserting
a nylon filament into the artery and 12 h later, the control
and injured brain samples were processed for TUNEL
staining as a marker of apoptotic cell death. Caspase-11
knockout mice exhibited markedly reduced population of
apoptotic cells induced by permanent occlusion of middle
cerebral artery at the level of striatum and hippocampus
(Fig. 1, B and C). This reduction was not due to the genetic
background effect in the knockout mice since wild-type
C57BL/6J and 129SvImJ mice showed no significant dif-
ference in the number of TUNEL-positive cells after
MCAO (data not shown).
 
Induction of Caspase-11 by Pathological Stimuli
 
Caspase-11 expression in normal healthy mice is undetect-
able by Western blot (Wang et al., 1996). We examined if
caspase-11 is upregulated by MCAO using immunoblot
and immunocytochemistry methods. Caspase-11 mutant
and wild-type control littermates were subjected to the
permanent MCAO for 12 h and the expression of caspase-
11 was examined (Fig. 2 A). As the majority of the cells
was not dying in these ischemic brains, and therefore only
a small portion of cells was expressing caspase-11, we had
to use immunoprecipitation to see caspase-11. We have
shown that the caspase-11 locus encodes two proteins of
38 and 43 kD (Wang et al., 1996). Interestingly, the 43-kD
species was induced only in the ischemic side of the brain,
whereas the 38-kD species was upregulated both in ipsilat-
eral and contralateral sides of the brain; in contrast, both
were absent in control brains. In the ischemic brain sam-
ples, immunoreactivity was strong in the cortical area (Fig.
2 B, a and b) and localized in the cytoplasm with occa-
sional filamentous or patchy condensation of the immu-
noreactivity (Fig. 2 B, e–g) and such staining was absent in
caspase-11 mutant mice (Fig. 2 B, c and d). This result
showed that caspase-11 is upregulated in a subpopulation
of cells in brain after ischemic injury.
To determine the cell types that express caspase-11 un- 
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der ischemic conditions, we carried out double-immuno-
staining on sections of ischemic brain samples using mAb
against caspase-11 and cell type marker antibodies. Cas-
pase-11 staining was found in cells positive for neuN (Fig.
2 C, a and b), a neuronal marker (Mullen et al., 1992), as
well as B4-isolectin (Fig. 2 C, d and e), a microglial marker
(Streit and Kreutzberg, 1987). Double-positive cells for
GFAP and caspase-11 were not detected (data not shown).
From these results, we concluded that caspase-11 is upreg-
ulated in subpopulations of neurons and microglial cells
after ischemic brain injury.
 
Inhibition of Caspase-3 Activation in Caspase-11 
Mutant Mice
 
Since caspase-3 has been shown to be a major downstream
caspase in apoptosis, we set out to test if resistance of
caspase-11 knockout mice to apoptosis induced by brain
ischemia is correlated with a deficiency in the activation of
caspase-3. Mice were challenged by MCAO and brains
were processed for immunohistochemistry. Antibody to
activated caspase-3, CM1, clearly labels a subpopulation
of cells in wild-type cortex after ischemic injury (Fig. 3, a
and b). This staining was significantly reduced in caspase-
11
 
2
 
/
 
2
 
 cortex that has been subjected to the same ischemic
treatment (Fig. 3, c and d). Untreated control wild-type
brains showed little staining with CM1 (Fig. 3, e and f).
These results suggest that caspase-11 is essential for the
activation of caspase-3 in a subpopulation of cortical neu-
rons and microglial cells after ischemic injury.
Since caspase-11 regulates the activation of both cas-
pase-1 and caspase-3, in ischemic tissues caspase-11 may
activate caspase-3 through direct proteolytic processing or
indirectly through regulating cytokines. We reasoned if
caspase-11 acts directly to activate caspase-3, we should be
able to detect the upregulated caspase-11 and activated
caspase-3 in the same cells. To test this possibility, we
coimmunostained ischemic brain samples with anticas-
pase-11 and CM1, and we found that a significant portion
of caspase-11–positive cells are also positive for CM1 (Fig.
3, g–i). Among 400 cells counted in the ischemic area, 27%
of the cells were positive for both caspase-11 and CM1,
7.3% were positive for caspase-11 only, and 2.3% were
positive for CM1 only. Importantly, we did not find any
caspase-11 single-positive cells that were right next to
CM1 single-positive cells (data not shown), thereby mak-
ing it highly unlikely that activated caspase-3 was medi-
ated by cytokines released from neighboring cells with
activated caspase-11. These results suggest that in the
cells that are positive for both caspase-11 and activated
caspase-3, the activation of caspase-3 is most likely me-
diated through direct processing of procaspase-3 by cas-
pase-11.
 
Activation of Caspase-3 by Caspase-11 In Vitro
 
Since caspase-11 appears to be able to activate caspase-3
in vivo independent of its ability to regulate cytokine pro-
cessing, we tested if caspase-11 can cleave procaspase-3 di-
rectly. Purified recombinant caspase-11 was incubated
with in vitro translated 
 
35
 
S-labeled caspase-3 and the re-
sulting products were visualized by autoradiography. As
shown in the Fig. 4 A, caspase-3 was found to be an excel-
Figure 1. Reduction of apoptotic cell numbers after ischemic
brain injury in caspase-112/2 mice. A, Western blot of spleen ly-
sate from 3 wild-type (1/1) and 4 caspase-1 (2/2) mice, probed
by anticaspase-11 (top), anticaspase-1 (middle) and antitubulin
(bottom). L929 cell lysate (L929) was used as a positive control.
B, TUNEL (a, c, and e) and Hoechst dye (b, d, and f) staining of
wild-type (a, b, e, and f) and caspase-112/2 (c and d) brains. a–d
are from ischemic brains and e and f are from untreated control
brain. Permanent ischemia was induced by occlusion of the left
middle cerebral artery using monofilament as described by Hara
et al. (1997a). 12 h after the occlusion, brains were processed for
TUNEL. C, Quantification of TUNEL-positive cells in the wild-
type and caspase-112/2 ischemic brain. The percentages of
TUNEL-positive cells were determined by the number of
TUNEL-positive cells divided by the number of Hoechst dye-
positive cells. TUNEL- and Hoechst dye-positive cells were
quantified using the Zeiss Axiovert microscope equipped with
Northern exposure software. Mean of the reading from five
brains is shown. Error bar represents standard error. 
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Figure 2. Induction of caspase-11 by ischemic brain injury. A,
Permanent ischemia was induced by 12-h occlusion of the left
middle cerebral artery. Wild-type ischemic (Isch), ipsilateral (L),
and contralateral (R), or sham-operated (con), ipsilateral (L),
and contralateral (R) sides of brain lysates were immunoprecipi-
tated with monoclonal anti-
caspase-11 antibody and
Western-blotted with anti-
caspase-11 mAb. IgG H and
IgG L indicate IgG heavy
and light chain, respectively.
Anticaspase-11 stains a weak
background band slightly
smaller than 38 kD some-
times in brain samples. B,
Wild-type and caspase-112/2
ischemic brains were immu-
nostained with anticaspase-11
(a, c, and e) and counter-
stained with Hoechst dye (b,
d, and f) 12 h after MCAO. e
and f are overlaid in g. C,
Wild-type ischemic brain 12 h
after the occlusion was dou-
ble-stained for caspase-11 (a)
and anti-NeuN as a neuronal
marker (b); caspase-11 (d)
and B4-isolectin as a microg-
lial cell marker (e). Counter-
stainings with Hoechst dye
are shown in c and f.
 
lent substrate for caspase-11. Caspase-11 cleaved pro-
caspase-3 much more readily than any of the other pro-
caspases (data not shown). To examine if caspase-11
cleaves caspase-3 at Asp
 
175
 
 between the large and the
small subunit of caspase-3, Asp
 
175
 
 of caspase-3 was mu-
tated to Ala, which changed IETD
 
175
 
 to IETA
 
175
 
. This mu-
tation completely blocked the cleavage of caspase-3 by
caspase-11 (Fig. 4 A). These results suggest that caspase-
11 may activate caspase-3 through direct proteolytic cleav-
age at IETD
 
175
 
.
To examine if purified caspase-11 can activate the
proteolytic activity of caspase-3, we incubated purified
caspase-11 with purified procaspase-3. While both active
caspase-11 and procaspase-3 were unable to cleave DEVD.
amc, a preferred substrate for caspase-3, incubation of
procaspase-3 with active caspase-11 resulted in cleavage of
DEVD.amc (Fig. 4 B, left). These results showed that
purified caspase-11 can activate procaspase-3 efficiently
through proteolytic cleavage. As a comparison, we incu-
bated equal amount of active caspase-11 as in Fig. 4 A with
equal amount of procaspase-1 as procaspase-3 in Fig. 4 A;
although incubating active caspase-11 with procaspase-1
can also result in the activation of caspase-1, as indicated
by YVAD.amc fluorogenic substrate, the activation of
procaspase-1 by caspase-11 was much less effective (Fig. 4
B, right).
A positional scanning synthetic combinatorial library
was developed to determine the specificity of caspases
(Thornberry et al., 1997). This method made use of the
fact that caspases cleave after an aspartic acid residue and
can cleave tetrapeptides terminating in Asp.AMC as effi-
cient fluorogenic substrates. The library is composed of
three separate sublibraries of 8,000 compounds each, con- 
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taining all the amino acid residue combinations at P2, P3,
and P4 positions (P4 P3 P2 D.AMC). Interestingly, when
the cleavage specificity of caspase-11 was tested in this li-
brary, we found that although caspase-11 is a member of
the caspase-1 subfamily based upon its sequence homol-
 
ogy, it prefers to cleave (I/L/V/P)EHD, which is similar to
the specificity of upstream caspases, such as caspase-8 and
-9 (Fig. 4 C). Since it has been well established that
caspase-8 or -9 can directly activate caspase-3 through pro-
teolytic cleavage (Muzio et al., 1996; Li et al., 1997), these
results further argue that caspase-11 can directly activate
caspase-3 under pathological conditions.
 
Processing of 43-kD Procaspase-11 by Active
Caspase-11 In Vitro
 
The caspase-11 locus encodes two polypeptide of 43- and
38-kD (Wang et al., 1996). Since caspase-11 cDNA under
the control of a heterologous promoter is transcripted and
translated into the same 43- and 38-kD in vitro and in cells
(Fig. 5, and data not shown), it is reasonable to assume
that they are the products of alternative starts of transla-
tion. In addition, only the 43-kD product would carry the
NH
 
2
 
-terminal tag (data not shown), which provides a fur-
ther support that the 38-kD product is initiated down-
stream from the Met for 43 kD, and therefore is missing
most of the prodomain of caspase-11. To elucidate the
functional difference of 43- and 38-kD products of cas-
pase-11, we incubated the purified bacterially expressed
procaspase-11 with in vitro translated, 
 
35
 
S-labeled full-
length caspase-11. Like all the other caspases, procaspase-
11 is autoprocessed when expressed in bacteria and there-
fore is proteolytically active (Fig. 4 and data not shown).
As shown in Fig. 5 A, purified bacterially expressed
procaspase-11 can process in vitro translated full-length
caspase-11 into a protein fragment of 30 kD (p30) and 10
kD (p10). Interestingly, the cleavage appears to target
preferentially at the 43-kD species, whereas the 38-kD
species is stable during the incubation. This result suggests
that the 43-kD caspase-11 protein product may be acti-
vated early in the apoptosis pathway.
To study if caspase-11 can be activated and processed
during apoptosis in culture, we chose the L929 cell line be-
cause it expresses high levels of caspase-11. Most of the
cell lines express undetectable amount of caspase-11 and
have to be induced with LPS to express caspase-11. The
L929 cells were treated with different amounts of etopo-
side and incubated overnight. The cell lysates made from
etoposide-treated L929 were Western blotted with anti-
caspase-11 mAb made against p10 of the caspase-11
(17D9). As shown in Fig. 5 B, the 43-kD product of
caspase-11 was processed into p30 during etoposide-
induced cell death, whereas the 38-kD remained stable.
We predict that the p30 is the caspase-11 fragment re-
moved of its N prodomain because it still can be recog-
nized by the mAb against the p10 subunit. This result is
consistent with our in vitro cleavage analysis and supports
the conclusion that the 43-kD product of caspase-11 is ac-
tivated more easily and earlier in apoptosis than that of
the 38-kD product.
 
Discussion
 
Since our analysis of caspase-11 showed that caspase-11
may be a very important regulator of apoptosis under
pathological conditions, it is critical to identify its human
ortholog. The obvious candidates for caspase-11 in human
Figure 3. Inhibition of caspase-3 activation in caspase-112/2
ischemic brain and costaining of caspase-11 and activated
caspase-3 in wild-type ischemic brain. 12 h after MCAO, wild-
type (a, b, and g–i) and caspase-112/2 (c and d) brains were dou-
ble-stained with CM1 (a and c) and Hoechst dye (b and d), or tri-
ple-stained with CM1 (g), anticaspase-11 antibody (h), and
Hoechst dye (i). As a control, untreated brain samples from wild-
type animal were stained with CM1 (e) and Hoechst dye (f). Sec-
tions from wild-type and caspase-112/2 brains were attached side
by side to the slides and incubated in the same drop of antibody
solution to ensure the identical experimental condition. Images
were exposed for the same amount of time using Phase 3 imaging
system and Northern exposure software. 
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are caspase-4 and -5, since they share the highest homol-
ogy among all known caspases with caspase-11; however,
caspase-4 expression appears to be present in unstimu-
lated cells (Kamada et al., 1997). The preferred cleavage
tetrapeptide substrates of caspase-4 and -5 are (W/L)EHD
(Thornberry et al., 1997), which differs from that of
caspase-11. While caspase-11 prefers LEHD as a sub-
strate, it does not cleave WEHD to a significant degree.
Thus, it is possible that either caspase-4 and -5 in human
may function like caspase-11 in mouse, but with a some-
what wider specificity; alternatively, the true ortholog of
caspase-11 in human remains to be identified. It will be
helpful to know whether other characteristics of caspase-
11 (such as its inducibility) are preserved in caspase-4 and/
or -5 to distinguish these possibilities.
The expression of caspase-11 is the most stringently reg-
ulated among all the caspases identified so far. Whereas
most of caspases can be detected in healthy, unstimulated
cells, caspase-11 expression is below the detection limit of
Northern and Western blots and its transcripts are only
detectable by reverse transcriptase PCR in most tissues
except intestine, where its expression can be detected in
unstimulated condition (Wang, S., S. Kang, and J. Yuan,
unpublished data). The expression of caspase-11 is highly
inducible by a variety of apoptosis stimuli, including isch-
emic brain injury, systemic inflammation, head trauma,
and even transfection of cultured cells (Wang, S., S. Kang,
and J. Yuan, unpublished data). Whereas the activation of
most caspases is mediated through recruitment into activa-
tion complexes, the activation of caspase-11 is regulated at
the transcriptional and translational level. We have ob-
served caspase-11 to form filamentous structures in cells
with high levels of caspase-11 expression (Fig. 2). Overex-
pression of caspase-8 has been shown to form filaments
that appear to be sufficient for their activation (Siegel et
al., 1998). It is possible that elevated caspase-11 protein
concentration in stimulated cells may be sufficient for it to
form filaments which results in its activation.
The present work, together with our previous study
(Wang et al., 1998), demonstrates that caspase-11 is a dual
activator of caspase-1 and -3 under pathological condi-
tions, although we cannot rule out a possibility that other
caspases are also acting downstream of caspase-11, as
caspase-2 and -7 are also cleaved by caspase-11 in vitro
(data not shown). Caspase-7 is similar to caspase-3 in its
specificity (Thornberry et al., 1997), so it is possible that
caspase-7 may contribute to the downstream effect of
caspase-11. Caspase-2, however, is unlikely to play a sig-
Figure 4. The cleavage specificity of caspase-11. A, Cleavage of caspase-3 by caspase-11. 35S-labeled in vitro translated caspase-3 wild-
type or D175A mutant substrates as indicated at the bottom were incubated at 308C for 2 h in the presence (1) or absence (2) of re-
combinant caspase-11 (1.16 mM) as indicated at the top. The cleavage of wild-type and mutant caspase-3 by caspase-11 was analyzed by
SDS-PAGE and autoradiography. There is a nonspecific protein product from the vector right below caspase-3 product that cannot be
recognized by anticaspase-3 antibody (data not shown). B, Activation of procaspase-3 by caspase-11. Purified recombinant procaspase-3
(indicated as C3 in the left panel, 1.04 mM), procaspase-1 (C1 in the right panel, 1 mM) or active caspase-11 (C11, 1.16 mM) was incu-
bated with acDEVD.amc for caspase-3 activation and acYVAD.amc for caspase-1 activation individually or together as indicated.
DEVDase or YVADase activity was followed by fluorogenic activity reading at 10-s interval at lex 5 380 nm, lex 5 460 nm. Represen-
tative data are shown out of four independent experiments. Note the significantly higher magnitude of activation of procaspase-3 com-
pared with procaspase-1. C, The substrate specificity of caspase-11 was determined by PS-SCL method as in Rano et al. (1997). The y
axis represents the rate of AMC production expressed as a percentage of the maximum rate observed in each experiment. The x axis
shows the positionally defined amino acids. The result indicates that caspase-11 prefers (I/L/V/P)EHD.The Journal of Cell Biology, Volume 149, 2000 620
nificant role in ischemic brain injury, as caspase-2 knock-
out mice did not show any resistance to MCAO (Bergeron
et al., 1998).
Caspase-11 has at least two downstream caspases. One
interesting question is whether there is cross-talk between
the two downstream caspases of caspase-11. We have
shown that although overexpression of caspase-1 cannot
induce caspase-112/2 EF cells to die, caspase-11 induced
apoptosis of caspase-12/2 EF cells efficiently (Wang et
al., 1998). Thus, caspase-1 is not required for caspase-11–
induced apoptosis, which supports our model that caspase-
11 can activate caspase-3 directly. On the other hand, al-
though caspase-1 is not required for caspase-11 to induce
apoptosis, caspase-1 activation may contribute to apopto-
sis in vivo indirectly. Intraventricular microinjection of
both YVAD.cmk and DEVD.fmk have been shown to re-
duce ischemic brain injury induced by MCAO with in-
triguing differences (Hara et al., 1997b). Intraventricular
injection of YVAD.fmk resulted in both reduction of in-
farction volume and of brain swelling. Interestingly, intra-
ventricular injection of DEVD.fmk decreased infarction
volume, but had no effect on brain swelling. As we have
shown that caspase-11 can mediate the activation of both
caspase-1 and caspase-3, such damage may be mediated
directly through proteolytic activation of caspase-3 and
apoptosis, and indirectly, through activating caspase-1 and
cytokine release, which causes brain swelling that may in
turn initiate additional apoptosis. Thus, the regulation of
both downstream caspases, caspase-1 and -3, by caspase-
11 may contribute to apoptotic damage under pathological
conditions.
Caspase-11 locus encodes two proteins of 38 and 43 kD
(Wang et al., 1996). We observed that the 43-kD protein is
the predominant protein product of caspase-11 cleaved
both in vivo during apoptosis and in vitro by autoprocess-
ing. We hypothesize that the 43-kD protein is the full-
length caspase-11 that can be autoactivated, whereas the
38-kD protein may be missing most of the CARD domain
that it may need to be activated by another caspase(s). In-
terestingly, the 43-kD species was induced only in the
ischemic side of the brain, whereas the 38-kD species was
upregulated both in the ipsilateral and contralateral side
of the brain. Cortical ischemia has been known to modify
metabolism and blood flow in nonischemic contralateral
brain areas (Feendy and Baron, 1986). It is possible that
the concurrent upregulation of 38-kD caspase-11 product
in the contralateral hemisphere may reflect activation in
homologous brain regions, the consequences of which
have not yet been identified.
Whereas caspase-11 can be activated by proteolytic
cleavage, the cleavage may not be essential for its activa-
tion, as we only observed its cleavage when its expression
levels are very high (Fig. 5; and Kang, S., S. Wang, and J.
Yuan, unpublished data). In LPS-stimulated mice, al-
though caspase-11 is induced in almost all tissues, its cleav-
age can only be observed in spleen where its expression is
the highest (Wang et al., 1996; Kang, S., and J. Yuan, un-
published results). It has been increasingly accepted that
at least long prodomain caspases can be activated without
cleavage (Stennicke et al., 1999). Alternatively, it remains
possible that the cleavage products of caspase-11 are un-
stable, and therefore, only when the levels of caspase-11
are very high can we observe its cleavage products. This is
certainly possible for caspase-11 in ischemic brain. As the
majority of the cells are not dying in these ischemic brains,
and therefore only a small portion of cells are expressing
caspase-11 that can only be observed through immunopre-
cipitation, we cannot find the cleavage product of caspase-
11 in all cases.
Neither caspase-1 knockout line can be induced to ex-
press caspase-11, whereas our caspase-11 knockout mouse
line expresses caspase-1 normally (Wang et al., 1998). This
may be due to the fact that caspase-1 and -11 are geneti-
cally closely linked (Li, P., personal communication) and
the disruption of genomic structure in caspase-1 has a neg-
ative effect on the expression of caspase-11. Preliminary
examination of caspase-11 locus in caspase-12/2 mice by
Southern blot and PCR showed that the locus of caspase-
11 is intact, suggesting that inability to induce caspase-11 is
not due to disruption of caspase-11 gene structure in
caspase-12/2 mice (Wang, S., and J. Yuan, unpublished re-
sults). Alternatively, the cytokines regulated by caspase-1,
Figure 5. Autoprocessing of 43-kD caspase-11 in vitro. A, Cleav-
age of caspase-11 in vitro. 1 ml of 35S-labeled caspase-11, in vitro
translated from its full-length cDNA (pS15), was mixed with 1 mg
of purified procaspase-11 (pS15) in a total volume of 10 ml. The
mixtures were incubated at 378C for the time indicated at the top
of the panel. The cleavage products of labeled procaspase-11 by
procaspase-11 enzyme were analyzed by SDS-PAGE and autora-
diography. B, Cleavage of caspase-11 in apoptosis. L929 cells
were incubated with indicated amounts of etoposide overnight,
which induced 50–80% of cells to die and the cleavage of
caspase-11 was determined by Western blot using anticaspase-11
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IL-1b, IL-1a, IL-18 (Ghayur et al., 1997), and interferon g
may have a positive feedback effect on caspase-11 expres-
sion. Therefore, the loss of cytokine production in cas-
pase-1 mutant mice may prevent the induction of caspase-
11. However, we have been unable to induce caspase-11
expression by coinjecting caspase-1 knockout mice with
LPS and IL-1b (Kang, S., and J. Yuan, unpublished data).
The loss of caspase-11 expression in caspase-1 knockout
mice complicated the interpretation as to why caspase-1
knockout mice are resistant to ischemic brain injury
(Schielke et al., 1998), because the caspase-11 mutation
alone has a strong effect on ischemic brain injury-induced
apoptosis. Thus, it remains to be resolved whether the loss
of caspase-1 expression alone is sufficient to inhibit isch-
emic brain injury-induced apoptosis. We predict, however,
that the loss of caspase-1 and the absence of cytokines,
such as IL-1 and IL-18, will have a significant impact on
ischemic brain injury-induced by swelling, which ulti-
mately contributes to the development of apoptosis.
Although our data demonstrated that caspase-11 can
directly activate caspase-3, we do not exclude a role for
cytokines in the regulation of cell death. Our previous
studies showed that IL-1b may promote cell death (Fried-
lander et al., 1996). One possibility is that cytokines, such
as IL-1b and interferon g, of which processing and secre-
tion of both are controlled by the caspase-11–caspase-1
pathway, may promote the upregulation of caspase-11 and
-1. Xu et al. (1998) have shown that interferon g can up-
regulate caspase-1 under certain conditions and our re-
sult showed that IL-1b can stimulate the production of
caspase-11. Thus, cytokines may contribute to apoptosis
by positively regulating the expression of caspases. On the
other hand, there is evidence that apoptosis may play a
key role in cytokine secretion. IL-1b is a cytokine that
lacks an obvious signal peptide and its mechanism of se-
cretion is still under debate. Whereas many cell types have
the capacity to produce IL-1, its release has been shown to
be restricted predominantly to monocytes/macrophages
and associated with apoptosis of producer cells (Hogquist
et al., 1991; Zychlinsky et al., 1994). Secretion of IL-1b
from U937 cells is partially inhibited by Bcl-2 overexpres-
sion (Lizard et al., 1997), suggesting apoptosis may play an
important role in regulating IL-1 b secretion in monocytic
cells. Perhaps controlling both apoptosis and cytokine se-
cretion through upregulation of a single caspase is advan-
tageous as a way to ensure immediate and complete elimi-
nation of damaged cells.
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